chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Ringing in ears constantly causing vertigo; Ringing in ears constantly causing vertigo; This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (Ringing in ears constantly causing vertigo) and VERTIGO (Ringing in ears constantly causing vertigo) in a 25-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunisation.     Concurrent medical conditions included Penicillin allergy and Allergy to antibiotic (Amoxicillin).   On 19-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 17-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On 20-Apr-2021, the patient experienced TINNITUS (Ringing in ears constantly causing vertigo) and VERTIGO (Ringing in ears constantly causing vertigo). On 18-May-2021, TINNITUS (Ringing in ears constantly causing vertigo) and VERTIGO (Ringing in ears constantly causing vertigo) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Concomitant product use was not provided by the reporter.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 21-Aug-2021: Follow up received contains no new information.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 25-year-old female patient (not pregnant) received bnt162b2 (BNT162B2), on 25Jan2022 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 23 years, in left arm for covid-19 immunisation; covid-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19 with paxlovid from 09Nov2023 to 09 nov2023.  The information on the batch/lot number for bnt162b2 has been requested and will be submitted if and when received.; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect product to the reported event Drug ineffective and COVID 19 cannot be ruled out.,Linked Report(s) : US-PFIZER INC-202300367621 Same patient, different drug, different event;
I experienced severe eczema on my right hand especially on my fingertips. I tolerated it for a few weeks using previously prescribed medication that did not help. My doctor put me on Celebrex and added a new cream for my hands. It took a few weeks for it to get better. They have also put me on Dupixent because it did not resolve and began spreading to my feet. I will have my 2nd Dupixent injection today. My hands are much improved and look almost normal. There is no more throbbing in the hands.
The pt experienced joint pain and swelling which had progress until notification of an MD on 10/11/99. The pt also experienced general malaise. Prednisone was prescribed. From follow-up info received on 1/28/00, it was reported that four days after receiving vaccination the pt's feet became swollen, red and painful. The pt developed trouble walking. Treatment with Prednisone (as a tapered dose) 20-15-10-5-5 was given. Regression strongly even by 11/2/99, feet were tender, slightly inflamed on toes. The pt reprotedly recovered as of 11/10/99 according to primary doctor. Follow up 9/23/02: during internal review of all files, it was deemed necessary to amend the report by updating the adverse event coding (added rash, pain, and abnormal gait). The AE's were also re-ranked according to their seriousness.
Headache, chills, muscle aches, and joint pain that lasted through the night. By morning, it was a more mild headache and minor muscle ache.
feeling itchy; itch could possibly be from dry skin; This is a spontaneous report from a contactable consumer.   A 75-years-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot# unknown, via an unspecified route of administration single dose on 17Jan2021 for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient experienced feeling itchy on Jan2021, itch could possibly be from dry skin on Jan2021. The outcome was unknown.    Information on Lot/batch number has been requested.
6 hours post-vaccine she started symptoms of temp of 101, achy, and fatigue
NONE NOTED, PATIENT WAS GIVEN WRONG VACCINE. ADMINISTERED PROQUAD TO AN ADULT INSTEAD OF THE SEPERATE MMR AND VARICELLA VACCINES.
6/16/99 1 1/2hr p/vax exp n/v, h/a, fever, chills went to the ER recv nausea rx went home feeling much better;
Administered vaccine that was stored at temperature between -80 degree Fahrenheit to -84 degree Fahrenheit; Administered vaccine that was stored at temperature between -80 degree Fahrenheit to -84 degree Fahrenheit; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree Fahrenheit to -84 degree Fahrenheit) and POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree Fahrenheit to -84 degree Fahrenheit) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 076C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Nov-2021 at 3:45 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 19-Nov-2021 at 3:45 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree Fahrenheit to -84 degree Fahrenheit). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree Fahrenheit to -84 degree Fahrenheit). At the time of the report, PRODUCT STORAGE ERROR (Administered vaccine that was stored at temperature between -80 degree Fahrenheit to -84 degree Fahrenheit) and POOR QUALITY PRODUCT ADMINISTERED (Administered vaccine that was stored at temperature between -80 degree Fahrenheit to -84 degree Fahrenheit) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided. No treatment medication information was provided.  It was reported that the vaccine was at frozen storage condition at the time of the temperature excursion. Excursion duration was 1 month.  On 19-Nov-2021, the Moderna COVID-19 vaccine vial went from the super cold freezer to the refrigerator. The vaccine was returned to the freezer/refrigerator/ultra cold freezer, or maintained at room temperature.  No vaccine state changes were noticed. The vaccine was never refrozen. None of the vials were punctured. No previous temperature excursion issues had happened.  The patient was given doses from a vial that were stored in an ultracold freezer which is colder than they should have been.   This case was linked to MOD-2021-402935 (Patient Link).
administered frozen Shingrix; This case was reported by a nurse via call center representative and described the occurrence of incorrect storage of drug in a 71-year-old male patient who received Herpes zoster (Shingrix) (batch number C43KM, expiry date 10th April 2023) for prophylaxis.   In March 2022, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.   Additional Information: GSK Receipt Date: 7-Apr-2022 Reporter's comments: The nurse administered frozen Shingrix vaccine to the patient within 7th March 2022 to 31st March 2022. The healthcare professional provided consent to follow up. Information within adverse event report was all the healthcare professional provided at this time. Additional Supportive Information: The patient received frozen Shingrix vaccine which led incorrect storage of drug. This was 1 of the 11 cases, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022061864:Same reporter. US-GLAXOSMITHKLINE-US2022061865:Same reporter. US-GLAXOSMITHKLINE-US2022061868:Same reporter US-GLAXOSMITHKLINE-US2022061866:Same reporter. US-GLAXOSMITHKLINE-US2022061860:Same reporter. US-GLAXOSMITHKLINE-US2022061871:Same reporter. US-GLAXOSMITHKLINE-US2022061872:Same reporter. US-GLAXOSMITHKLINE-US2022061873:Same reporter. US-GLAXOSMITHKLINE-US2022061874:Same reporter. US-GLAXOSMITHKLINE-US2022061875:Same reporter.
Patient had itchy throat ~20 min after vaccinatino. Known hx of allergy to NSAID and has an EpiPen. Reported cough and SOB. Gave Benadryl 25 mg with positive response after 10 minutes. Symptoms resolved, stable, released from vaccination site.
WHENEVER STANDING WOULD LOSE CONTROL OF BLADDER; EXTREMELY BAD HEADACHE; GENERAL MUSCLE ACHES AND PAIN/MUSCLES WASN'T DOING GOOD; VERY TIRED; This spontaneous case was reported by a consumer and describes the occurrence of URINARY INCONTINENCE (WHENEVER STANDING WOULD LOSE CONTROL OF BLADDER), HEADACHE (EXTREMELY BAD HEADACHE), MYALGIA (GENERAL MUSCLE ACHES AND PAIN/MUSCLES WASN'T DOING GOOD) and FATIGUE (VERY TIRED) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced URINARY INCONTINENCE (WHENEVER STANDING WOULD LOSE CONTROL OF BLADDER), HEADACHE (EXTREMELY BAD HEADACHE), MYALGIA (GENERAL MUSCLE ACHES AND PAIN/MUSCLES WASN'T DOING GOOD) and FATIGUE (VERY TIRED). At the time of the report, URINARY INCONTINENCE (WHENEVER STANDING WOULD LOSE CONTROL OF BLADDER), HEADACHE (EXTREMELY BAD HEADACHE), MYALGIA (GENERAL MUSCLE ACHES AND PAIN/MUSCLES WASN'T DOING GOOD) and FATIGUE (VERY TIRED) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported. No treatment details were reported.
Cellulitis (L) shoulder with Abscess.  fever of 102.6 - hospital admit for I & d with drainage.
arm rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH (arm rash) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RASH (arm rash). At the time of the report, RASH (arm rash) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided.  No treatment information was reported.
Information has been received from a registered nurse concerning a female patient who on an unspecified date, was vaccinated with the second dose of GARDASIL (lot# not reported). Subsequently, the patient called the nurse and left message on nurses line which reported that she had an allergic reaction to her second dose of GARDASIL and she was inquiring if she should get her third dose. It was reported that the patient did not have a reaction on the first dose of GARDASIL. No medical attention was sought. At the time of this report, the patient's outcome was unknown. No further information is available.
One week after receiving flu shot, my left arm from shoulder to wrist went numb and extremely painful. Approx. 6 weeks later my left hand became paralyzed.
Received Pfizer Covid Booster (3rd shot) and Quadrivalent Flu Vaccine together. Did not experience adverse reactions with either of these vaccine prior. 12 hours after receiving vaccines- Fever of 103.1f, aches, immobilizing headache.
rash, welts on arms, shoulders, torso-itching treated w/celestone, rx given for pred;
The headache has started off and on. It has gotten worse and felt like a migraine behind the left; fatigue; headache; This spontaneous case was reported by an other health care professional (subsequently medically confirmed) and describes the occurrence of MIGRAINE (The headache has started off and on. It has gotten worse and felt like a migraine behind the left), FATIGUE (fatigue) and HEADACHE (headache) in a 54-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012L20A and 010M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 05-Feb-2021, the patient experienced MIGRAINE (The headache has started off and on. It has gotten worse and felt like a migraine behind the left), FATIGUE (fatigue) and HEADACHE (headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, MIGRAINE (The headache has started off and on. It has gotten worse and felt like a migraine behind the left), FATIGUE (fatigue) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided.  Treatment details included At 4:15AM, he took 2 Tylenol tablets that morning. On 07 Feb 2021, he took 2 Tylenol tablets at, 4PM and nothing today.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An elderly patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in Oct2022 as dose 5 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Apr2023) Negative, notes: After two negative Ag tests 48 hours apart; (Apr2023) Negative, notes: After two negative Ag tests 48 hours apart; (15Apr2023) Positive, notes: tested positive again; (2023) Positive, notes: symptoms plus positive Ag tests. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical Course: Patient took the full Paxlovid treatment after first COVID infection (symptoms plus positive Ag tests) from 05Apr2023 to 10Apr2023. Then the patient had two negative Ag tests 48 hours apart.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected. Sender's Comments: Linked Report(s): US-PFIZER INC-202300157934 Same patient, different product;
The incident took place after a successful injection to the patient. The patient reported no health issues with the vaccine after receiving it. The incident involved a finger stick with a contaminated needle after the injection to place.
Pneumovax given Rt deltoid 02/04/08.  Pt developed redness, swelling and tenderness posterior right arm 3x5cm.
This spontaneous report as received from an office manager refers to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions and concomitant medications were not reported. No previous drug reactions or allergies were reported. On 08-AUG-2016 the patient was vaccinated with improperly stored VARIVAX (dosing details were not reported) (lot # M010480, expiry date: 03-JAN-2018). No adverse effects were reported. There was no product quality complaint involved. This is one of the two reports received from the same reporter. Additional information has been requested.
Information has been received from a RN concerning a 40 month old premature female with Down's syndrome, a transitional AV canal, and no allergies who on 04Jun03 was vaccinated SC in the left thigh with a first dose of varicella virus vaccine live (lot643592/0807M). Concomitant vaccination on the same day included an IM fourth dose of pneumococcal 4 6B 9V 14 18C 19F 23F conj vaccine (CRM197) (Prevnar) (lot491577). There was no illness at the time of vaccination. On 09Oct05, the pt developed a fever, congestion, and one lesion. Over the next few days she was not feeling well and on 11Oct05 she was taken to the doctor's office. She had developed more lesions and had a continuing fever. The maximum number of lesions was 14. Treatment was symptomatic relief and isolation. On 18Oct05, she developed four new lesions after the initial lesions crusted over. No diagnostic laboratory tests were performed. At the time of the report, the pt was recovering. A product quality complaint was not involved. Follow up information was received from the RN who reported that on 09Oct05, the pt was seen in the office for cold symptoms, fever and vomiting on 04Oct05 and 07oct05. On 09Oct05, she was noted to have pimples on her face. She was seen in the office again on 11Oct05 for crusty lesions on her face. She was diagnosed with probable varicella on 18Oct05. She was seen again in the office on 19Oct05 for infected pox on her face. She was put on mupirocin (Bactroban) for impetigo. She was isolated until all the pox crusted. The pt recovered on 24Oct05. Neither the pt or her sibling had any adverse events following prior vaccination. Probable varicella and impetigo were considered to be other important medical events by the reporter (OMIC). No further information is expected.
Urticaria - extreme itchiness all over body. Welting with any kind of pressure from clothing or carried items; also if contact with skin by any external item or scratches. Usually subsides within half an hour but then arises elsewhere on body.
syncope (lasting 1 minute), vomiting (lasting 1 minute), dizziness lasting over 45 minutes. Nausea lasting over 45 minutes. Anxiety and rapid heart rate lasting over 20 minutes
Swollen supraclavicular lymph node developed  1 week after vaccination.  Swollen node has not resolved 8 days after onset.
vaccine was administered outside of storage recommendations. patient came in on 6/4/2021 at 2:15pm to re-vaccinate
ex 31+5 weeker, requiring 5 week stay in NICU for prematurity. Received 1st Hep B on DOL 1, repeated at 1 month of age as outpatient. 12 days later noted swelling at injection site, 4 weeks after shot parents noted erythema of R thigh, presented to care. Found to have an abscess, s/p I+D - gram stain noted gram positive cocci in pairs and clusters
Information has been received from a physician concerning a 7 year old female who on 02/24/98 was vaccinated with a dose of varicella virus vaccine live (Lot # 622682/0181E). There was no concomitant medication. On approximately 10/29/03 the pt experienced breakthrough chickenpox. It was reported that the pt's "best friend" in school as well as the friend's siblings had chickenpox and these children were not vaccinated. The pt was seen by the physician with multiple lesions on her face, truncal was heaviest, scattered on the limb and 2 in the head. The lesions had only been out for approximately 14 hours when seen. There were papules, vesicles and 1 scab on the head and her temperature was 99.6-100. There was no other apparent cause than chickenpox. There was no treatment required and no product quality complaint involved. Additional information has been requested.
She reportedly received her second Hep A (into her left deltoid (above her SP scar) November 2007. She noted immediately that this shot was significantly more painful than her previous shots. The next am the area was swollen, red, and tender to touch. She denies fever, chills, myalgia, lightheadedness, etc. The site remained swollen and tender. After about 3 days she noted very pruritic satellite papules. She would scratch to the point of excoriation. Topical steroid cream and Claritin were ineffective. The inflammation/papules spontaneously resolved after about 7-10 days. About 2 weeks later she noted a quarter-sized area of swelling and tenderness at the same site. Over the next few days it expanded to approximately 3" in diameter with peripheral small pruritic papules (neither vesicles nor pustules). She denied preceding trauma to the area. Over the past 6 months, the localized reaction has recurred in cyclic fashion about every 2 weeks, lasting about 7-10 days (four times). The reactions are neither worse nor better in severity or duration. Always involves exactly the same location over her deltoid. Reaction is not related to exercise, identifiable exposures, foods, medications, or her menses.
Since I received my first vaccine, I experienced some tightness in my upper left arm, had a radiating sensation to my hand.  I received my second dose and I am still experiencing the rightness sensation to my left arm and hand. I saw Dr. performed an U/S of the left upper extremity to check for any blood clots. Dr. is doing some physical therapy.